Biomerica, Inc. is a biomedical technology firm that invents, secures intellectual property for, produces, and globally distributes diagnostic and therapeutic solutions aimed ...
Biomerica, Inc. (BMRA) is a NASDAQ-listed biomedical technology company headquartered in Irvine, California. The company’s core purpose is to improve medical decision-making through diagnostic testing products. Biomerica invents and secures intellectual property and then develops, produces, and distributes diagnostic solutions on a global basis. Its diagnostics are designed to analyze patient samples such as blood, urine, or stool and identify or quantify clinically relevant biological substances—supporting the detection, monitoring, and characterization of a range of medical conditions.
From a product and service perspective, Biomerica’s business centers on in-vitro diagnostic (IVD) kits and related testing solutions. Public company descriptions emphasize applications including gastrointestinal disorders, food sensitivities, diabetes, and other esoteric or specialized diagnostic evaluations. The company’s testing kits can be used to pinpoint illnesses and to quantify minute concentrations of target compounds (e.g., bacteria, hormones, antibodies, antigens, or other analytes) present in bodily fluids or waste. Commercially, the company distributes through channels that include physicians’ clinics, retail pharmacies, and hospital/clinical laboratories, aligning its go-to-market approach with providers that administer testing and with buyers seeking diagnostic products for clinical workflows.
Biomerica also pursues development programs beyond its existing diagnostic catalog. For example, the company has referenced initiatives such as InFoods, described as a diagnostic-guided therapy technology for irritable bowel syndrome, along with product development efforts related to Helicobacter pylori and COVID-19 diagnostic tools. These efforts reflect a strategy of leveraging diagnostics to guide therapeutic decisions and expanding into additional diagnostic indications.
In terms of company scale and operating footprint, Biomerica is relatively small, with an employee count reported around 54 (full-time and part-time combined), placing it in the 0–100 employee band. Financially, the provided dataset indicates lower profitability in the most recent trailing-twelve-month snapshot, with negative margins (e.g., net profit margin around -96.5% and operating loss metrics). Liquidity indicators such as a current ratio above 2.0 are also shown in the dataset, suggesting working-capital coverage, while cash-flow-related measures appear pressured (free cash flow and operating cash flow ratios shown as negative). For cost/production and operations, working capital and inventory turnover metrics suggest inventory and receivables management are material factors for day-to-day execution. In the absence of detailed product-level BOM disclosures in the provided data, the cost structure can be inferred at a high level as typical for an IVD manufacturer: R&D and regulatory/quality activities, manufacturing/packaging of test components, quality systems, and sales/distribution costs.
Key leadership includes CEO Zackary S. Irani, with the company’s executive management also including roles such as CCO and CFO as indicated in the provided leadership excerpts. Overall, BMRA’s profile is that of a niche IVD/biomedical diagnostics company: IP-driven development, diagnostic manufacturing and commercialization, and ongoing pipeline efforts to broaden diagnostic indications and potentially support diagnostic-guided therapeutic approaches.
Key Raw Material Vendor A (Undisclosed)Key Raw Material Vendor B (Undisclosed)Lancer Orthodontics, Inc.OTC:LANZSpecialty Chemical & Biological Reagent Manufacturers (Various)Plastic Consumables & Packaging Suppliers (Various)
Downstream
9
Henry Schein, Inc.NASDAQ:HSICCVS Health CorporationNYSE:CVSWalmart Inc.NYSE:WMTPhoenix Airmid Biomedical Corp.CanAlt Health LaboratoriesMajor Healthcare Distributor in Vietnam (Undisclosed)Large European Clinical Laboratory Chain (Undisclosed)Confidential Life Sciences Company (Undisclosed)International Distributors (~100+ entities)
